How Much Weight Can You Lose Taking Wegovy?

Last reviewed: June 30, 2026

Last updated: June 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Clinical Weight Loss Data: What the Research Shows

The STEP clinical trial program evaluated semaglutide in over 4,500 participants with overweight or obesity. Participants receiving semaglutide 2.4 mg weekly lost an average of 15 kg (33 pounds) over 68 weeks, representing approximately 15% of their baseline body weight. In comparison, participants receiving placebo lost only 2.6 kg on average. These results represent some of the most significant weight loss outcomes ever documented in a pharmaceutical intervention trial.

Weight loss typically follows a predictable timeline during semaglutide treatment. Most patients experience initial results within the first 4 to 8 weeks, with continued loss accelerating through months 3 to 6. By 12 weeks, many individuals report 5% to 10% body weight reduction. The rate of loss then plateaus around week 20 as your body reaches a new metabolic equilibrium. Individual variation is substantial—some patients lose 20% or more of their body weight, while others achieve 8% to 12% reduction depending on genetic and behavioral factors.

Individual Factors That Determine Your Weight Loss Amount

The PlexusDx Precision Peptide Genetic Test analyzes GIPR and FTO — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Starting body weight, age, and baseline metabolic health significantly influence absolute weight loss numbers. A person starting at 280 pounds may lose 45 to 65 pounds on semaglutide, while someone starting at 220 pounds might lose 25 to 40 pounds—both representing similar percentage reductions. Consistent lifestyle modifications—including reduced calorie intake, increased physical activity, and improved sleep—amplify semaglutide's effects. Patients who combine medication with dietary changes and exercise consistently outperform those relying on medication alone.

Semaglutide Dose Escalation and Weight Loss Progression

PlexusDx delivers semaglutide through a structured dose escalation protocol, starting at lower doses and gradually increasing every 4 weeks. Your initial dose may be 0.25 mg, advancing to 0.5 mg, 1 mg, 1.7 mg, and potentially reaching the maximum therapeutic dose of 2.4 mg. Higher doses generally produce greater weight loss, though the relationship is not perfectly linear—some patients achieve maximum benefit at 1.7 mg, while others require the full 2.4 mg dose. PlexusDx pricing remains flat throughout your entire dose progression, meaning your monthly cost stays at $189 even as your dose increases. This commitment to transparent pricing removes barriers to reaching your optimal therapeutic dose without financial penalty.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Comparing PlexusDx Semaglutide to Brand-Name Alternatives

PlexusDx semaglutide is manufactured by licensed 503A compounding pharmacies and contains identical active pharmaceutical ingredients to brand-name Wegovy. The clinical weight loss profile is equivalent because semaglutide is semaglutide—the medication mechanism, potency, and body response are identical regardless of manufacturer. PlexusDx is $189/mo month-to-month, or from $149/mo on the 6-month plan flat-rate pricing, compared to brand-name pricing that often exceeds $900 to $1,300 monthly before insurance. HSA and FSA accounts cover PlexusDx medication costs, making this option accessible to patients across all 50 states without insurance requirements.

Licensed 503A compounding pharmacies must meet identical United States Pharmacopeia (USP) standards as brand manufacturers for sterility, potency, and purity. PlexusDx medications undergo third-party testing and quality verification before dispensing. The primary differences between compounded and brand semaglutide are cost and accessibility—not safety or efficacy. Patients choosing PlexusDx receive medically supervised treatment with the same expected weight loss outcomes as any other semaglutide source, but with significant financial advantages and guaranteed availability.

Sustaining Weight Loss After Reaching Your Goal

Weight loss sustainability depends on whether you continue semaglutide therapy and maintain lifestyle changes. Clinical follow-up studies show that patients who discontinue semaglutide gradually regain approximately 50% of lost weight within one year if they revert to baseline eating patterns. Conversely, patients who continue semaglutide at their maintenance dose while sustaining dietary and exercise improvements maintain 85% to 95% of achieved weight loss long-term. This pattern suggests semaglutide is most effective as a continuous therapy rather than a short-term intervention.

PlexusDx supports long-term treatment continuation through predictable monthly pricing and ongoing genetic insights from your Precision Peptide Genetic Test results. Your initial test identifies which peptide pathways your body responds to most effectively, allowing your PlexusDx clinician to optimize your regimen for sustained results. Regular monitoring appointments track your weight progression, metabolic markers, and medication tolerability, ensuring your treatment plan evolves with your changing health status. Many patients view semaglutide as a foundational therapy for metabolic management rather than temporary weight loss intervention.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight did people lose in the clinical trials?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How quickly will I see weight loss results?

Most patients notice initial weight loss within 4 to 8 weeks of starting semaglutide. Significant results typically appear by 12 weeks, with continued loss through month 6. Your dose escalation schedule and individual metabolism influence the exact timeline, but PlexusDx clinicians track your progress monthly and adjust your protocol based on your specific response.

Why does PlexusDx charge flat pricing instead of by dose?

PlexusDx pricing remains constant at $189 per month for semaglutide injections regardless of whether you're at 0.25 mg or 2.4 mg doses. This ensures you can reach your optimal therapeutic dose without financial barriers. Your dose may need to go up. Your price won't.

What happens to my weight if I stop taking semaglutide?

Research shows patients typically regain about 50% of lost weight within one year after stopping semaglutide. However, those who maintain lifestyle changes and continue taking semaglutide sustain 85-95% of their weight loss long-term. PlexusDx supports ongoing treatment with transparent pricing and continuous clinician oversight.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Wegovy For Losing Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.